BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

...Ventures led the A round, which also saw participation from SV Health, Takeda Ventures and Astellas...
...of employees: 16Funds raised: $42 millionInvestors: Sofinnova Partners, Lightstone  Ventures, SV Health Investors, Takeda Ventures, Astellas...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...in NSCLC patients for treatment with AZ’s Iressa gefitinib or Tagrisso osimertinib, or Tarceva erlotinib from Astellas Pharma Inc....
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...Committee and regulatory authorities will review the trial data and investigate whether the deaths were treatment-related.Astellas...
...Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm Therapeutics Inc. Aurinia Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Astellas Pharma Inc. Janus...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...III trial of SNG001 in COVID-19 patients by year-end.Astellas...
...with heart failure. Consensus estimates provided by FactSet. BC Staff Astellas AtheroChem Synairgen Boehringer...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...neuromuscular diseases, the most advanced of which, amyotrophic lateral sclerosis (ALS) therapy reldesemtiv, is partnered with Astellas Pharma Inc....
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...said it would not offer new shares in the process.Padcev meets urothelial cancer endpointPadcev enfortumab vedotin-ejfv from Astellas Pharma Inc....
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK).Astellas Pharma Inc....
...Therapeutics Inc. Inovio Pharmaceuticals Inc. OncoSec Medical Inc. AstraZeneca plc Moderna Inc. Astellas Pharma Inc. Oncorus...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...therapies. Modalis first entered a research collaboration with Astellas Pharma Inc....
...not disclosed.The biotech is also partnered with Astellas...
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...he served as SVP and general counsel and helped lead the sale of the company to Astellas Pharma Inc....
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

...Phase I testing of SJX-653, and Astellas Pharma Inc. (Tokyo:4503) is evaluating fezolinetant in a Phase III study.Last year, Astellas...
Items per page:
1 - 10 of 2586
BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

...Ventures led the A round, which also saw participation from SV Health, Takeda Ventures and Astellas...
...of employees: 16Funds raised: $42 millionInvestors: Sofinnova Partners, Lightstone  Ventures, SV Health Investors, Takeda Ventures, Astellas...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

...in NSCLC patients for treatment with AZ’s Iressa gefitinib or Tagrisso osimertinib, or Tarceva erlotinib from Astellas Pharma Inc....
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...Committee and regulatory authorities will review the trial data and investigate whether the deaths were treatment-related.Astellas...
...Agency (EMA) U.S. Food and Drug Administration (FDA) Gilead Sciences Inc. Galapagos N.V. Karyopharm Therapeutics Inc. Aurinia Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Astellas Pharma Inc. Janus...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...III trial of SNG001 in COVID-19 patients by year-end.Astellas...
...with heart failure. Consensus estimates provided by FactSet. BC Staff Astellas AtheroChem Synairgen Boehringer...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...neuromuscular diseases, the most advanced of which, amyotrophic lateral sclerosis (ALS) therapy reldesemtiv, is partnered with Astellas Pharma Inc....
BioCentury | Sep 24, 2020
Finance

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

...said it would not offer new shares in the process.Padcev meets urothelial cancer endpointPadcev enfortumab vedotin-ejfv from Astellas Pharma Inc....
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

...Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK).Astellas Pharma Inc....
...Therapeutics Inc. Inovio Pharmaceuticals Inc. OncoSec Medical Inc. AstraZeneca plc Moderna Inc. Astellas Pharma Inc. Oncorus...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...therapies. Modalis first entered a research collaboration with Astellas Pharma Inc....
...not disclosed.The biotech is also partnered with Astellas...
BioCentury | Aug 26, 2020
Finance

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

...he served as SVP and general counsel and helped lead the sale of the company to Astellas Pharma Inc....
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

...Phase I testing of SJX-653, and Astellas Pharma Inc. (Tokyo:4503) is evaluating fezolinetant in a Phase III study.Last year, Astellas...
Items per page:
1 - 10 of 2586